Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

MRD-driven strategies and novel immunotherapies for multiple myeloma

Myeloma Knowledge Exchange 2021 (MyKE Myeloma)

Published: 25 Oct 2021

Views: 1126

Rating:

Save

Prof Simon Harrison - Peter MacCallum Cancer Centre, Melbourne, Australia

Prof Simon Harrison speaks to ecancer about MRD-driven strategies and novel immunotherapies for multiple myeloma.

He talks about his presentation at MyKE Myeloma 2021.

Initially, Prof Harrison talks about the MRD-driven strategies in NDMM.

He then explains some of the novel immunotherapies for multiple myelomas.

Prof Harrison concludes by discussing bispecific antibodies, CAR T therapies and ADCs.

Related Videos

The 5-year long-term outcomes of radiation technique for locally advanced NSCLC

Dr Stephen Chun - MD Anderson, Houston, USA

The 5-year long-term outcomes of radiation technique for locally advanced NSCLC ( Dr Stephen Chun - MD Anderson, Houston, USA )

OncoAlert Round Up for August 25th - 31st, 2023

Dr Gil Morgan - Executive Director, OncoAlert

OncoAlert Round Up for August 25th - 31st, 2023 ( Dr Gil Morgan - Executive Director, OncoAlert )

Choosing Wisely in radiology Tanzania

Dr Revelian Iramu - Ocean Road Cancer Institute, Dar es Salaam, Tanzania

Choosing Wisely in radiology Tanzania ( Dr Revelian Iramu - Ocean Road Cancer Institute, Dar es Salaam, Tanzania )

Combination of camonsertib plus PARPi shows clinical activity in DDR-aberrant...

Dr Timothy Yap - The University of Texas MD Anderson Cancer Center, Houston, USA

Combination of camonsertib plus PARPi shows clinical activity in DDR-aberrant tumours ( Dr Timothy Yap - The University of Texas MD Anderson Cancer Center, Houston, USA )

Choosing Wisely to mitigate financial toxicity in cancer care in Africa

Dr Penina Mnandi - Ocean Road Cancer Institute, Dar es Salaam, Tanzania

Choosing Wisely to mitigate financial toxicity in cancer care in Africa ( Dr Penina Mnandi - Ocean Road Cancer Institute, Dar es Salaam, Tanzania )

CheckMate 9ER: aRCC patients on nivolumab plus cabozantinib achieved deeper...

Dr Cristina Suarez - Vall d’Hebron University Hospital, Catalonia, Spain

CheckMate 9ER: aRCC patients on nivolumab plus cabozantinib achieved deeper responses vs sunitinib ( Dr Cristina Suarez - Vall d’Hebron University Hospital, Catalonia, Spain )

Intratumoral BO-112 with pembrolizumab shows benefit in advanced melanoma...

Dr Iván Márquez-Rodas - Hospital General Universitario Gregorio Marañón, Madrid...

$Intratumoral BO-112 with pembrolizumab shows benefit in advanced melanoma refractory to anti-PD-1 therapy ( Dr Iván Márquez-Rodas - Hospital General Universitario Gregorio Marañón, Madrid, Spain )$

Recurrent non-invasive breast tumours may not always be related to the primary...

Dr Tanjina Kader - University of Melbourne, Melbourne, Australia

Recurrent non-invasive breast tumours may not always be related to the primary lesion ( Dr Tanjina Kader - University of Melbourne, Melbourne, Australia )

Novel bispecific checkpoint inhibitor MEDI5752 shows promise for advanced solid...

Dr Ben Tran - Peter MacCallum Cancer Centre, Melbourne, Australia

Novel bispecific checkpoint inhibitor MEDI5752 shows promise for advanced solid tumours ( Dr Ben Tran - Peter MacCallum Cancer Centre, Melbourne, Australia )

More from ecancer